

INDEPENDENT RESEARCH  
UPDATE

13th January 2016

Food & Beverages

Bloomberg	BN FP
Reuters	DANO.PA
12-month High / Low (EUR)	67.5 / 53.1
Market capitalisation (EURm)	38,472
Enterprise Value (BG estimates EURm)	45,484
Avg. 6m daily volume ('000 shares)	1,638
Free Float	98.0%
3y EPS CAGR	10.5%
Gearing (12/14)	66%
Dividend yield (12/15e)	2.86%

YE December	12/14	12/15e	12/16e	12/17e
Revenue (EURm)	21,144	22,430	23,157	24,529
EBIT (EURm)	2,662	2,922	3,120	3,407
Basic EPS (EUR)	2.63	2.94	3.20	3.54
Diluted EPS (EUR)	2.62	2.93	3.19	3.53
EV/Sales	2.19x	2.03x	1.94x	1.81x
EV/EBITDA	x	x	x	x
EV/EBIT	17.4x	15.6x	14.4x	13.0x
P/E	22.4x	20.0x	18.4x	16.6x
ROCE	9.8	10.8	11.5	12.6



# Danone

The best is still to come!

Fair Value EUR74 vs. EUR69 (price EUR58.74)

**BUY**

Analysis of the challenges brought about by changes in the food industry strengthens our positive conviction on Danone. We estimate that only 16% of its portfolio, corresponding to yoghurts in Europe (excluding CIS), is at risk. We have lifted our Fair Value from EUR69 to EUR74 mainly to take account of the roll-over in our estimates.

■ **Danone's portfolio is globally sheltered from upheaval in the food industry and as such, its growth potential remains intact.** The group has communicated a sustainable medium-term growth rate of 7-10% for water and early life nutrition and 6-8% for medical nutrition. Only 16% of total sales, corresponding to yoghurts in Europe (excluding CIS), are at risk. **The group has mapped out a specific plan to restore its performance and has set credible financial targets. The first results are positive.** Markets such as Spain, Italy (both stable), Germany, Poland and Belgium are showing signs of improvement. The recovery of Actimel is ongoing. Since Q4 2014, the brand has posted sales growth during three quarters. The gross margin of fresh dairy products in Europe increased by 140bp in H1 2015 excluding milk price effects.

■ **This analysis strengthens our positive conviction on Danone.** We estimate that sales should increase by 4.5% in 2016 (+4.2% this year at the low-end of guidance for 4-5%), stemming from growth of 1.8% in fresh dairy products, 5% in water, 9% in early life nutrition and 7.5% in medical nutrition. The trading operating profit margin is set to rise by 50bp in 2016 (+40bp in 2015). **We have lifted our Fair Value from EUR69 to EUR74 mainly to take account of our estimates roll-over. The share still has a discount relative to peers.** It is trading on 12-month forward P/E of 20.1x (based on a consensus 2.5% below our estimates) compared with 21.2x for Nestlé (our expectations are 1.6% below consensus) and 20.4x for Unilever.




Analyst:  
**Virginie Roumage**  
33(0) 1.56.68.75.22  
vroumage@bryangarnier.com


Sector Analyst Team:  
Nikolaas Faes  
Loïc Morvan  
Antoine Parison  
Cédric Rossi

Danone

2015 Sales breakdown by Division



2015 Sales breakdown by Region



Company description

Born in 1972 thanks to the merger of BSN and Gervais Danone, Danone has refocused on four core activities (Fresh Dairy products, Waters, Early Life Nutrition and Medical Nutrition) in a limited number of markets in which it intends to be the leader.

Simplified Profit & Loss Account (EURm)	2012	2013	2014	2015e	2016e	2017e
Sales	20,869	21,298	21,144	22,430	23,157	24,529
Change (%)	8.0%	2.1%	-0.7%	6.1%	3.2%	5.9%
Like-for-like change (%)	5.4%	4.8%	4.7%	4.2%	4.5%	5.9%
Trading operating profit	2,959	2,809	2,662	2,922	3,120	3,407
Change (%)	4.1%	-5.1%	-5.2%	9.7%	6.8%	9.2%
Operating income						
Total financial expenses	(302)	(263)	(312)	(319)	(288)	(268)
Income before taxes	2,445	1,865	1,839	2,078	2,797	3,099
Reported income tax	(712)	(604)	(599)	(662)	(730)	(823)
Share of profit of associates	54.0	289	14.0	105	118	123
Net profit	1,787	1,550	1,253	1,522	2,184	2,399
Non-controlling interests	115	128	134	131	145	153
Net profit Group share	1,672	1,422	1,119	1,391	2,039	2,246
Underlying net income_group share	1,818	1,636	1,561	1,776	1,932	2,139
Change (%)	3.9%	-10.0%	-4.6%	13.8%	8.8%	10.7%
<b>Cash flows from operating activities</b>						
Working capital variation	(333)	(217)	(57.0)	(124)	(99.0)	(94.9)
Capex, net	(976)	(1,039)	(984)	(1,054)	(1,088)	(1,153)
Other	206	113	59.0	0.0	0.0	0.0
Free cash flow excluding exceptional items	2,088	1,549	1,401	1,603	1,737	1,945
Exceptionals	0.0	(121)	(123)	30.0	0.0	0.0
Free cash flow reported	2,088	1,428	1,277	1,603	1,737	1,945
M&A	(300)	(1,330)	(1,404)	(1,273)	0.0	0.0
Dividends	(1,083)	(953)	(417)	(311)	(1,017)	(1,107)
Other	(365)	(819)	746	732	(200)	(200)
Net debt	6,292	7,966	7,764	7,013	6,493	5,854
<b>Property, plant and equipment</b>						
Intangibles assets	16,265	16,308	16,234	16,385	16,538	16,693
Cash & equivalents	1,269	969	880	299	319	26.6
current assets	6,923	7,850	7,449	7,376	7,517	7,450
Total assets	29,537	30,928	31,747	31,833	32,101	32,094
L & ST Debt	9,522	11,927	11,142	10,121	9,621	8,690
Others liabilities	7,761	8,272	8,860	9,159	9,554	9,544
Shareholders' funds	12,191	10,694	11,696	12,504	12,878	13,810
Total Liabilities	17,283	20,199	20,002	19,280	19,175	18,235
<b>Trading operating margin</b>						
Reported tax rate	29.10	32.40	32.60	31.83	26.12	26.54
Underlying net income_group share	8.71	7.68	7.38	7.92	8.34	8.72
ROE	13.72	13.30	9.57	11.12	15.84	16.27
ROIC	11.36	10.42	9.77	10.77	11.49	12.58
Gearing based on net debt	51.35	74.25	66.10	55.87	50.23	42.24
Gearing based on net financial debt	24.65	44.01	44.33	41.32	36.10	29.07
Pay out ratio	48.09	52.11	57.27	57.27	57.27	57.27
Number of shares, diluted	603	588	596	606	606	606
<b>Basic underlying EPS</b>						
Diluted underlying EPS	3.01	2.78	2.62	2.93	3.19	3.53
% change	4.3%	-7.7%	-5.9%	12.0%	8.8%	10.7%
BVPS	20.22	18.19	19.62	20.65	21.27	22.81
Operating cash flows	4.19	3.84	3.81	4.18	4.50	4.96
FCF	3.46	2.63	2.35	2.65	2.87	3.21
Net dividend	1.45	1.45	1.50	1.68	1.83	2.02

Source: Company Data; Bryan, Garnier & Co ests.

# 1. Solid fundamentals

**Analysis of the challenges brought about by changes in the food industry (see sector report: A spicier dish) strengthens our positive conviction on Danone. We estimate that only 16% of its portfolio, corresponding to yoghurts in Europe (excluding CIS), is at risk. The group has mapped out a specific plan to restore its performance and has set precise financial targets.** It is now forecasting growth of 3-5% in fresh dairy product sales by 2020 thanks to changes in the marketing model (more focused on emotion), innovation (Danonino pocket etc.) and the refocusing of resources on eight of its brands (Activia, Actimel, Vitalinea, Danio, Oikos, Danette, Danonino, Danone) that generate more than 80% of sales and profits. Danone has also indicated that it is planning to improve underlying EBIT margin by 200bp (excluding forex) between 2015 and 2020, primarily by streamlining its portfolio and optimising operations. **The first results are positive.** Signs are encouraging in markets such as Spain, Italy (both are stable), Germany, Poland and Belgium. The recovery of Actimel is ongoing. Since Q4 2014, the brand has posted growth in three quarters. Trends at Activia have stabilised, although they remains in negative territory. The gross margin in fresh dairy products in Europe increased by 140bp in H1 2015, excluding the milk price effect! Danone should reach the low-end of its sales guidance in 2017. We are forecasting sales growth in yoghurts of 3.5%, implying a stabilisation in Europe, growth of 3% in the US and CIS and 5% in Asia-Pacific/Latin America. We have increased our underlying EBIT margin estimates for fresh dairy products over the next three years and now expect a 40bp increase to 9.7% in 2015 (vs. 9.5% previously). Over the following two years, the margin should rise by respectively 30bp and 50bp to 10% and 10.5%.

**Other divisions are generally sheltered from upheaval in the food industry. We believe that early life nutrition should be the main growth driver in coming years.** In China (22% of sales on our estimates), the group has restored its pre-Fonterra market share of 15%. It boasts very strong positions in e-commerce (legal in B2C and illegal in C2C) with market share of 50%! Consumer interest remains robust for international brands, especially those stemming from the Netherlands, Germany, Ireland and New Zealand. After the disposal of Dumex to Yashili, Danone will no longer be present in the declining modern trade circuit, contrary to Nestlé and Mead Johnson which are overexposed. Apart from possible synergies, this operation should enable Danone to deepen its relations with the Chinese government and extend its distribution to tier-4 cities and beyond the e-commerce channel. **In 2016, the water division is likely to slow due to destocking of the Mizone brand, which is suffering from the slowdown in the Chinese economy. However, the category's potential remains significant. The group communicated on a sustainable medium-term growth pace of 7-10% for water and baby-food and 6-8% for medical nutrition.**

**In addition to the recovery plan for fresh dairy products, strong measures are be implemented at the group level in order to reach the 2020 target for profitable and sustainable growth:**

- **Organisational changes.** The "One Danone" plan aims to integrate the support functions (HR, IT etc.) in order to reduce costs and enable better expertise. During 2016, 30 clusters are to be created. This new organisation should be fully operational in 2017.
- **Changes to variable remuneration criteria for managing directors.** At present, variable remuneration is two-thirds based on sales and one-third on margins. Although exactly what changes are to be made were not stated at the Investor Day, Emmanuel Faber clearly said that he would like to place the focus more on profitability.
- **Changes to budgeting systems.** Danone is to abandon its annual budget and adopt a quarterly budget on a rolling basis. The allocation of resources will be more dynamic, enabling the group to rapidly re-allocate funds depending on requirements.

## 2. Estimates

We estimate that sales should increase by 4.5% in 2016 (+4.2% this year at the low-end of guidance for 4-5%), stemming from growth of 1.8% in fresh dairy products, 5% in water, 9% in early life nutrition and 7.5% in medical nutrition. The trading operating profit margin is set to rise 50bp in 2016 (+40bp in 2015) and 40bp the following year. The decline in financial expenses should contribute to EPS growth of 8.8% in 2016 and 10.7% in 2017. These forecasts remain globally unchanged (2015-17 EPS estimates up 1%) since although we have raised the margins for yoghurts, we have reduced our organic sales growth forecast for water.

**Fig. 1: Sales forecasts by division**

<i>EURm</i>	2014	2015e	2016e	2017e
<b>GROUP</b>				
<b>Sales</b>	<b>21 144</b>	<b>22 430</b>	<b>23 157</b>	<b>24 529</b>
Reported variation	-0,7%	6,1%	3,2%	5,9%
FX variation	-5,5%	2,1%	-0,3%	0,0%
External variation	0,1%	-0,2%	-0,9%	0,0%
<b>Organic variation</b>	<b>4,7%</b>	<b>4,2%</b>	<b>4,5%</b>	<b>5,9%</b>
<i>% price/mix</i>	6,2%	3,4%	2,3%	3,0%
<i>% volume</i>	-1,5%	0,8%	2,2%	2,9%
<b>FRESH DAIRY PRODUCTS</b>				
<b>Sales</b>	<b>11 129</b>	<b>11 083</b>	<b>11 227</b>	<b>11 620</b>
Reported variation	-5,6%	-0,4%	1,3%	3,5%
<b>Organic variation</b>	<b>1,5%</b>	<b>0,6%</b>	<b>1,8%</b>	<b>3,5%</b>
<b>EARLY LIFE NUTRITION</b>				
<b>Sales</b>	<b>4 397</b>	<b>4 939</b>	<b>5 208</b>	<b>5 708</b>
Reported variation	3,1%	12,3%	5,5%	9,6%
<b>Organic variation</b>	<b>6,1%</b>	<b>8,6%</b>	<b>9,0%</b>	<b>9,6%</b>
<b>WATERS</b>				
<b>Sales</b>	<b>4 186</b>	<b>4 817</b>	<b>5 019</b>	<b>5 370</b>
Reported variation	7,3%	15,1%	4,2%	7,0%
<b>Organic variation</b>	<b>11,6%</b>	<b>8,2%</b>	<b>5,0%</b>	<b>7,0%</b>
<b>MEDICAL NUTRITION</b>				
<b>Sales</b>	<b>1 432</b>	<b>1 592</b>	<b>1 703</b>	<b>1 831</b>
Reported variation	6,7%	11,1%	7,0%	7,5%
<b>Organic variation</b>	<b>7,9%</b>	<b>7,5%</b>	<b>7,5%</b>	<b>7,5%</b>

Source: Danone, Bryan, Garnier & Co

**Fig. 2: EBIT estimates by division**

<i>EURm</i>	2014	2015e	2016e	2017e
<b>GROUP</b>				
<b>EBIT</b>	<b>2 662</b>	<b>2 922</b>	<b>3 120</b>	<b>3 407</b>
Reported variation	-5,2%	9,7%	6,8%	9,2%
<b>Margin</b>	<b>12,59%</b>	<b>13,02%</b>	<b>13,47%</b>	<b>13,89%</b>
Change in bp	-60	43	45	42
<i>LFL</i>	-12	26	22	42
<i>FX</i>	-28	9	2	0
<i>Scope</i>	-20	10	21	0
<b>FRESH DAIRY PRODUCTS</b>				
<b>EBIT</b>	<b>1 033</b>	<b>1 078</b>	<b>1 119</b>	<b>1 215</b>
Reported variation	-15,4%	4,4%	3,8%	8,6%
<b>Margin</b>	<b>9,28%</b>	<b>9,73%</b>	<b>9,97%</b>	<b>10,46%</b>
Change in bp	-107	45	24	49
<b>EARLY LIFE NUTRITION</b>				
<b>EBIT</b>	<b>828</b>	<b>912</b>	<b>1 022</b>	<b>1 119</b>
Reported variation	-1,0%	10,1%	12,1%	9,5%
<b>Margin</b>	<b>18,83%</b>	<b>18,45%</b>	<b>19,63%</b>	<b>19,61%</b>
Change in bp	-79	-39	128	-2
<b>WATERS</b>				
<b>EBIT</b>	<b>539</b>	<b>636</b>	<b>658</b>	<b>720</b>
Reported variation	5,9%	18,0%	3,4%	9,5%
<b>Margin</b>	<b>12,88%</b>	<b>13,20%</b>	<b>13,10%</b>	<b>13,41%</b>
Change in bp	-16	34	-10	31
<b>MEDICAL NUTRITION</b>				
<b>EBIT</b>	<b>262</b>	<b>296</b>	<b>321</b>	<b>352</b>
Reported variation	7,4%	13,0%	8,5%	9,8%
<b>Margin</b>	<b>18,28%</b>	<b>18,58%</b>	<b>18,84%</b>	<b>19,24%</b>
Change in bp	12	31	26	39

Source: Danone, Bryan, Garnier & Co

### 3. Valuation

We reiterate our Buy recommendation. We have lifted our Fair Value from EUR69 to EUR74 to take account of the roll-over in our estimates and the increase in our EPS forecasts over the next three years (+1%).

**Fig. 3: DCF**

EURm	2016e	2017e	2018e	2019e	2020e	2021e	2022e	2023e	2024e	2025e
Gross cash flow	3 432	3 688	3 821	4 071	4 333	4 560	4 761	4 934	5 073	5 176
CF variation		7,5%	3,6%	6,6%	6,4%	5,2%	4,4%	3,6%	2,8%	2,0%
-Capital expenditure	1088	1153	1222	1296	1374	1446	1478	1531	1540	1571
-WCR variation	-99	-95	-101	-107	-113	-119	-124	-129	-132	-135
<b>=Operating free cash flow</b>	<b>2 442</b>	<b>2 630</b>	<b>2 699</b>	<b>2 882</b>	<b>3 072</b>	<b>3 233</b>	<b>3 408</b>	<b>3 532</b>	<b>3 666</b>	<b>3 740</b>
Discounting rate	7,9%									
Perpetual growth rate	2,0%									
Discounted free cash flow	2264	2260	2149	2127	2102	2050	2004	1924	1851	1751
Discounted free cash flow sum	20 483									
+Discounted terminal value	30 349									
<b>=Total</b>	<b>50 832</b>									
-Minority interest	49									
+Financial assets	2 146									
-Net debt	7 013									
-Provisions	818									
<b>=Total</b>	<b>45 098</b>									
Number of shares	606									
<b>DCF per share</b>	<b>74</b>									

Source: Danone, Bryan, Garnier & Co

Danone's 12-month forward P/E only stands at 20.1x (on the basis of a consensus 2.5% lower than our estimates) compared with 21.2x for Nestlé (our expectations are 1.6% below consensus), while **its metrics are more attractive:**

**Fig. 4: Organic sales growth**

	2015e	2016e	2017e
Danone	4.2%	4.5%	5.9%
Nestlé	4.2%	4.5%	4.9%

**Fig. 5: EPS growth**

	2015e	2016e	2017e
Danone	12%	8.8%	10.7%
Nestlé	-3.6%	3.7%	7.6%

**Fig. 6: FCF yield**

	2015e	2016e	2017e
Danone	4.4%	4.8%	5.4%
Nestlé	4.2%	4.4%	4.6%

**Fig. 7: Change in ROIC**

	2015e	2016e	2017e
Danone	10.8%	7.3%	9.8%
Nestlé	-0.4%	3.3%	8.8%

Source of all charts: Danone, Nestlé, Bryan, Garnier & Co



## Price Chart and Rating History

### Danone



#### Ratings

Date	Ratings	Price
08/07/15	BUY	EUR58.09

#### Target Price

Date	Target price
20/10/15	EUR69
08/07/15	EUR71



## Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

### Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements including a SWOT analysis, positive momentum, technical aspects and the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements including a SWOT analysis, positive momentum, technical aspects and the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

### Distribution of stock ratings

BUY ratings 72%

NEUTRAL ratings 0%

SELL ratings 28%

## Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	No
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	No
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	No
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	No
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	No
6	Investment banking agreement	A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.	No
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

Summary of Investment Research Conflict Management Policy is available [www.bryangarnier.com](http://www.bryangarnier.com)



**BRYAN, GARNIER & CO**

<b>London</b>	<b>Paris</b>	<b>New York</b>	<b>Geneva</b>	<b>New Delhi</b>
Beaufort House 15 St. Botolph Street London EC3A 7BB Tel: +44 (0) 207 332 2500 Fax: +44 (0) 207 332 2559 Authorised and regulated by the Financial Conduct Authority (FCA)	26 Avenue des Champs Elysées 75008 Paris Tel: +33 (0) 1 56 68 75 00 Fax: +33 (0) 1 56 68 75 01 Regulated by the Financial Conduct Authority (FCA) and the Autorité de Contrôle prudentiel et de résolution (ACPR)	750 Lexington Avenue New York, NY 10022 Tel: +1 (0) 212 337 7000 Fax: +1 (0) 212 337 7002 FINRA and SIPC member	rue de Grenus 7 CP 2113 Genève 1, CH 1211 Tel +4122 731 3263 Fax+4122731 3243 Regulated by the FINMA	The Imperial Hotel Janpath New Delhi 110 001 Tel +91 11 4132 6062 +91 98 1111 5119 Fax +91 11 2621 9062

#### **Important information**

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available.